Arizona Cancer Center Gets Bristol-Myers Squibb Grant

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

TUCSON--The Arizona Cancer Center has received a 5-year, $500,000 Bristol-Myers Squibb Unrestricted Cancer Research Grant. Sydney E. Salmon, MD, Regents Professor of Medicine and director of the center, will serve as the grant administrator. Dr. Salmon announced the new funding at a ceremony held to dedicate the center’s $22.5 million expansion project adding 30 new cancer research laboratories to the center.

TUCSON--The Arizona Cancer Center has received a 5-year, $500,000 Bristol-Myers Squibb Unrestricted Cancer Research Grant. Sydney E. Salmon, MD, Regents Professor of Medicine and director of the center, will serve as the grant administrator. Dr. Salmon announced the new funding at a ceremony held to dedicate the center’s $22.5 million expansion project adding 30 new cancer research laboratories to the center.

Recent Videos
Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Isatuximab quadruplet therapy for patients with multiple myeloma prolonged progression-free survival when compared with VRd triplet therapy.
Retrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Prospective trial data may help guide treatment planning for patients with inflammatory bowel disease planning to undergo radiotherapy.
Samantha Shenoy, NP, MSN, suggests that support groups may help comfort patients experiencing adverse effects negatively impacting quality of life.
Samantha Shenoy, NP, MSN, emphasized educating patients with multiple myeloma to help prepare them for potential taste alterations after talquetamab.
Related Content